Status:
ENROLLING_BY_INVITATION
Breast Cancer PET/CT Imaging With 68Ga-pAKTi
Lead Sponsor:
Fudan University
Conditions:
Breast Cancers
PIK3CA Mutation-Related Tumors
Eligibility:
FEMALE
18+ years
Brief Summary
Abnormal activation of the PI3K-AKT signaling pathway in breast cancer patients is closely associated with tumor progression. Phosphorylated AKT (p-AKT) serves as a key indicator of pathway activation...
Eligibility Criteria
Inclusion
- Voluntarily signs the informed consent form.
- Age ≥ 18 years.
- Pathologically confirmed or highly suspected breast cancer based on conventional imaging.
- Estimated life expectancy \> 3 months as determined by the physician.
- Agrees to practice strict contraception for at least 28 days following the PET/CT examination.
- Willing and able to comply with the study protocol.
- Has not undergone surgical resection of the lesion.
- Has participated in molecular testing at the Precision Oncology Center of Fudan University Shanghai Cancer Center, and harbors a PIK3CA mutation, PTEN mutation, or upregulation of the PI3K-AKT-mTOR pathway.
Exclusion
- Pregnant or breastfeeding women.
- Unable to lie still on the PET/CT scanner bed during the examination or intolerant to PET imaging.
- Participation in another interventional clinical trial within 1 month prior to screening.
- Patients who are lost to follow-up.
- Any other condition that, in the opinion of the investigator, may interfere with the study or make the subject unsuitable for participation.
Key Trial Info
Start Date :
April 21 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06943313
Start Date
April 21 2025
End Date
December 31 2026
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, China